目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 31)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 BIOMARKERS MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED IN THE REPORT
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 36)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
FIGURE 4 BIOMARKERS MARKET: BREAKDOWN OF PRIMARIES
2.1.2.1 Key industry insights
2.2 MARKET SIZE ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2020
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF ALL BIOMARKERS PRODUCTS
FIGURE 7 BIOMARKERS MARKET: CAGR PROJECTIONS, 2021-2026
FIGURE 8 BIOMARKERS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS OPPORTUNITIES, AND CHALLENGES
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH LIMITATIONS
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 47)
FIGURE 10 BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD BILLION)
FIGURE 11 BIOMARKERS MARKET SHARE, BY TYPE, 2020
FIGURE 12 BIOMARKERS MARKET, BY DISEASE INDICATION, 2021 VS. 2026 (USD BILLION)
FIGURE 13 BIOMARKERS MARKET, BY APPLICATION, 2021−2026
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF THE BIOMARKERS MARKET

4 PREMIUM INSIGHTS (Page No. - 51)
4.1 BIOMARKERS MARKET OVERVIEW
FIGURE 15 THE GROWING IMPORTANCE OF COMPANION DIAGNOSTICS IS A KEY FACTOR EXPECTED TO DRIVE THE GROWTH OF THE BIOMARKERS MARKET
4.2 ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & COUNTRY (2020)
FIGURE 16 CONSUMABLES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2020
4.3 EFFICACY BIOMARKERS MARKET, BY TYPE, 2020
FIGURE 17 THE PREDICTIVE BIOMARKERS SEGMENT IS PROJECTED TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 54)
5.1 MARKET DYNAMICS
FIGURE 18 BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.1.1 MARKET DRIVERS
5.1.1.1 The growing importance of companion diagnostics
TABLE 1 RECENT DEVELOPMENTS IN COMPANION DIAGNOSTICS
5.1.1.2 Increasing prevalence of cancer worldwide
TABLE 2 GLOBAL CANCER INCIDENCE, 2020 VS. 2040
TABLE 3 LIST OF FDA-APPROVED BIOMARKERS FOR DIFFERENT TYPES OF CANCER
5.1.1.3 Increasing funds & grants for biomarker research
5.1.1.4 Continuous product innovations
TABLE 4 PRODUCT LAUNCHES, 2018−2021
5.1.2 RESTRAINTS
5.1.2.1 High capital investments and lengthy timelines for biomarker development
TABLE 5 TIMEFRAME FOR BIOMARKER DEVELOPMENT
5.1.3 OPPORTUNITIES
5.1.3.1 Personalized medicine
FIGURE 19 PERCENTAGE OF ONCOLOGY TRIALS INCORPORATING BIOMARKERS
TABLE 6 BIOMARKERS OF CARDIOVASCULAR DISEASE (CVD)
5.1.3.2 Emerging economies
5.1.4 CHALLENGES
5.1.4.1 Challenges associated with biomarker validation
5.1.4.2 Technical issues related to sample collection & storage
5.2 IMPACT OF COVID-19 ON THE BIOMARKERS MARKET
5.3 REGULATORY ASSESSMENT
5.3.1 INTRODUCTION
5.3.2 BIOMARKER QUALIFICATION IN THE US
5.3.3 BIOMARKER QUALIFICATION IN THE EU
5.3.4 BIOMARKER ACCEPTANCE IN DRUG DEVELOPMENT IN THE EU AND THE US
5.3.5 METHOD: EMA APPROVALS
5.3.6 METHOD: FDA APPROVALS
5.3.7 COMPANION DIAGNOSTICS
5.4 VALUE CHAIN ANALYSIS
FIGURE 20 BIOMARKERS MARKET: VALUE CHAIN ANALYSIS
5.5 TECHNOLOGICAL ANALYSIS
5.5.1 IMMUNOASSAYS
5.5.1.1 Immunohistochemistry (IHC)
5.5.1.2 Flow cytometry
5.5.1.3 Flow cytometry ELISA
5.5.2 NEXT-GENERATION SEQUENCING (NGS)
5.5.3 POLYMERASE CHAIN REACTION (PCR)
5.5.4 IN SITU HYBRIDIZATION
5.5.5 MICROARRAYS
5.5.6 MASS SPECTROMETRY
5.6 PORTER’S FIVE FORCES ANALYSIS
TABLE 7 BIOMARKERS MARKET- PORTER’S FIVE FORCES ANALYSIS
5.6.1 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
5.6.2 BARGAINING POWER OF SUPPLIERS
5.6.3 BARGAINING POWER OF BUYERS
5.6.4 THREAT OF SUBSTITUTES
5.6.5 THREAT OF NEW ENTRANTS
5.7 PATENT ANALYSIS
5.7.1 NUMBER OF PUBLICATIONS OVER LAST 10 YEARS
5.7.2 TOP 20 GRANTED PATENT OWNERS (US) IN LAST 20 YEARS
5.7.3 TOP 10 PLAYERS WITH HIGHEST NO. OF PATENT APPLICATIONS
5.7.4 LIST OF RECENT PATENTS
5.8 SUPPLY CHAIN ANALYSIS
FIGURE 21 DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
5.8.1 KEY INFLUENCERS
5.9 ECOSYSTEM ANALYSIS OF THE BIOMARKERS MARKET
FIGURE 22 ECOSYSTEM ANALYSIS OF THE BIOMARKERS MARKET
5.9.1 ROLE IN THE ECOSYSTEM
5.10 Y.C., YCC SHIFT
FIGURE 23 YC-YCC SHIFT FOR THE BIOMARKERS MARKET
5.11 RANGES/ SCENARIOS
FIGURE 24 DEPENDING ON HOW THE UNCERTAINTIES UNFOLD, WE SEE A SPECTRUM OF SCENARIOS FOR THE BIOMARKERS MARKET - 2020

6 BIOMARKERS MARKET, BY PRODUCT & SERVICE (Page No. - 79)
6.1 INTRODUCTION
TABLE 8 BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD BILLION)
6.2 CONSUMABLES
6.2.1 THE HIGHER FREQUENCY OF REPEATED PURCHASES OF CONSUMABLES TO DRIVE THE MARKET GROWTH
TABLE 9 BIOMARKER CONSUMABLES MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 10 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 11 EUROPE: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 12 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
6.3 SERVICES
6.3.1 THE GRADUAL SHIFT FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING OF SERVICES IS EXPECTED TO SUPPORT MARKET GROWTH
TABLE 13 BIOMARKER SERVICES MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 14 NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 15 EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 16 ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
6.4 SOFTWARE
6.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS BY PHARMACEUTICAL COMPANIES TO SUPPORT THE MARKET GROWTH
TABLE 17 BIOMARKER SOFTWARE MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 18 NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 19 EUROPE: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 20 ASIA PACIFIC: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2019-2026 (USD BILLION)

7 BIOMARKERS MARKET, BY TYPE (Page No. - 86)
7.1 INTRODUCTION
TABLE 21 BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
7.2 EFFICACY BIOMARKERS
TABLE 22 EFFICACY BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 23 EFFICACY BIOMARKERS MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 24 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 25 EUROPE: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 26 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.2.1 PREDICTIVE BIOMARKERS
7.2.1.1 Wide applications of predictive biomarkers in personalized medicine and companion diagnostics drive the growth of this segment
TABLE 27 PREDICTIVE BIOMARKERS MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 28 NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 29 EUROPE: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 30 ASIA PACIFIC: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.2.2 SURROGATE BIOMARKERS
7.2.2.1 The use of surrogate biomarkers helps accelerate drug development and shorten timelines for regulatory approval
TABLE 31 SURROGATE BIOMARKERS MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 32 NORTH AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 33 EUROPE: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 34 ASIA PACIFIC: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.2.3 PHARMACODYNAMIC BIOMARKERS
7.2.3.1 Increasing utilization of pharmacodynamic biomarkers in the selection & optimization of drug doses supports segment growth
TABLE 35 PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 36 NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 37 . EUROPE: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 38 ASIA PACIFIC: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.2.4 PROGNOSTIC BIOMARKERS
7.2.4.1 Prognostic biomarkers help in predicting the recurrence of diseases
TABLE 39 PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 40 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 41 EUROPE: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 42 ASIA PACIFIC: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.3 SAFETY BIOMARKERS
7.3.1 WIDE APPLICATIONS OF SAFETY BIOMARKERS IN DRUG DISCOVERY & DEVELOPMENT IS EXPECTED TO FUEL MARKET GROWTH
TABLE 43 SAFETY BIOMARKERS MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 44 NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 45 EUROPE: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 46 ASIA PACIFIC: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.4 VALIDATION BIOMARKERS
7.4.1 VALIDATION BIOMARKERS ENABLE IN THE EVALUATION OF DIAGNOSTIC SYSTEMS
TABLE 47 VALIDATION BIOMARKERS MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 48 NORTH AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 49 EUROPE: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 50 ASIA PACIFIC: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)

8 BIOMARKERS MARKET, BY DISEASE INDICATION (Page No. - 100)
8.1 INTRODUCTION
TABLE 51 BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2026 (USD BILLION)
8.2 CANCER
8.2.1 INCREASING ADOPTION OF BIOMARKERS IN CANCER RESEARCH & DIAGNOSIS IS EXPECTED TO DRIVE THE MARKET GROWTH
TABLE 52 LIST OF FDA-APPROVED BIOMARKERS FOR CANCER
TABLE 53 BIOMARKERS MARKET FOR CANCER, BY REGION, 2019-2026 (USD BILLION)
TABLE 54 NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 55 EUROPE: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 56 ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2019-2026 (USD BILLION)
8.2.2 SOLID BIOPSY
8.2.2.1 Solid biopsy provides the mutations from within the tumors
8.2.3 LIQUID BIOPSY
8.2.3.1 A liquid biopsy helps detect circulating tumor cells
TABLE 57 CANCER DISEASE INDICATION MARKET, BY TEST TYPE, 2019-2026 (USD BILLION)
8.3 INFECTIOUS DISEASES
8.3.1 THE INCREASING PREVALENCE OF INFECTIOUS DISEASES ARE EXPECTED TO INCREASE THE DEMAND FOR BIOMARKERS
TABLE 58 BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019-2026 (USD BILLION)
TABLE 59 NORTH AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 60 EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 61 ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD BILLION)
8.4 IMMUNOLOGICAL DISORDERS
8.4.1 INCREASING ADOPTION OF BIOMARKERS FOR VARIOUS IMMUNOLOGICAL DISORDERS ARE EXPECTED TO DRIVE THE MARKET GROWTH
TABLE 62 BIOMARKERS FOR IMMUNOLOGICAL DISORDERS
TABLE 63 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2019-2026 (USD BILLION)
TABLE 64 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 65 EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 66 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019-2026 (USD BILLION)
8.5 NEUROLOGICAL DISORDERS
8.5.1 IMMUNOASSAYS ARE WIDELY USED IN THE DIAGNOSIS OF NEUROLOGICAL DISORDERS
TABLE 67 BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2019-2026 (USD BILLION)
TABLE 68 NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 69 EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 70 ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2019-2026 (USD BILLION)
8.6 CARDIOVASCULAR DISORDERS
8.6.1 THE INCREASING PREVALENCE OF CVD IS EXPECTED TO INCREASE THE DEMAND FOR CARDIAC BIOMARKERS
TABLE 71 BIOMARKERS FOR CARDIOVASCULAR DISORDERS
TABLE 72 BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2019-2026 (USD BILLION)
TABLE 73 NORTH AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 74 EUROPE: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 75 ASIA PACIFIC: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2019-2026 (USD BILLION)
8.7 OTHER DISEASE INDICATIONS
TABLE 76 BIOMARKERS FOR RENAL DISORDERS
TABLE 77 ENDOCRINE BIOMARKERS
TABLE 78 BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2019-2026 (USD BILLION)
TABLE 79 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 80 EUROPE: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 81 ASIA PACIFIC: BIOMARKERS MARKET SIZE FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2019-2026 (USD BILLION)

9 BIOMARKERS MARKET, BY APPLICATION (Page No. - 116)
9.1 INTRODUCTION
TABLE 82 BIOMARKERS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
9.2 DIAGNOSTICS
9.2.1 THE INCREASING USE OF BIOMARKERS FOR THE DIAGNOSIS OF VARIOUS DISEASES TO DRIVE THE GROWTH OF THIS APPLICATION SEGMENT
TABLE 83 BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION, 2019-2026 (USD BILLION)
TABLE 84 NORTH AMERICA: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 85 EUROPE: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 86 ASIA PACIFIC: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019-2026 (USD BILLION)
9.3 DRUG DISCOVERY & DEVELOPMENT
9.3.1 BIOMARKERS PLAY A KEY ROLE AS BIOLOGICAL INDICATORS IN THE DEVELOPMENT OF NEW DRUGS
TABLE 87 BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2019-2026 (USD BILLION)
TABLE 88 NORTH AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 89 EUROPE: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 90 ASIA PACIFIC: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2019-2026 (USD BILLION)
9.4 PERSONALIZED MEDICINE
9.4.1 INCREASING APPLICATIONS OF BIOMARKERS IN PERSONALIZED MEDICINE FOR TARGETED THERAPIES DRIVES THE MARKET GROWTH
TABLE 91 SELECTED PERSONALIZED MEDICINE DRUGS AND RELEVANT BIOMARKERS
TABLE 92 BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2019-2026 (USD BILLION)
TABLE 93 NORTH AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 94 EUROPE: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 95 ASIA PACIFIC: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2019-2026 (USD BILLION)
9.5 DISEASE RISK ASSESSMENT
9.5.1 BIOMARKERS ARE WIDELY USED FOR THE CHARACTERIZATION OF TOXICITY IN DISEASE DIAGNOSIS & DRUG DEVELOPMENT PROCESSES
TABLE 96 BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY REGION, 2019-2026 (USD BILLION)
TABLE 97 NORTH AMERICA: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 98 EUROPE: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 99 ASIA PACIFIC: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2019-2026 (USD BILLION)
9.6 OTHER APPLICATIONS
TABLE 100 BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2019-2026 (USD BILLION)
TABLE 101 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 102 EUROPE: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 103 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019-2026 (USD BILLION)

10 BIOMARKERS MARKET, BY REGION (Page No. - 127)
10.1 INTRODUCTION
TABLE 104 BIOMARKERS MARKET, BY REGION, 2019-2026 (USD BILLION)
10.2 NORTH AMERICA
FIGURE 25 NORTH AMERICA: MARKET SNAPSHOT
TABLE 105 NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 106 NORTH AMERICA: BIOMARKERS MARKET, BY PRODUCT, 2019-2026 (USD BILLION)
TABLE 107 NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 108 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 109 NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
TABLE 110 NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2026 (USD BILLION)
10.2.1 US
10.2.1.1 The US is expected to dominate the biomarkers market in North America during the forecast period
TABLE 111 US.: BIOMARKERS MARKET, BY PRODUCT, 2019-2026 (USD BILLION)
TABLE 112 US: BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 113 US: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 114 US: BIOMARKERS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
TABLE 115 US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2026 (USD BILLION)
10.2.2 CANADA
10.2.2.1 The increasing incidence of cancer drives the growth of biomarker research in Canada
TABLE 116 CANADA: BIOMARKERS MARKET, BY PRODUCT, 2019-2026 (USD BILLION)
TABLE 117 CANADA: BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 118 CANADA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 119 CANADA: BIOMARKERS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
TABLE 120 CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2026 (USD BILLION)
10.3 EUROPE
TABLE 121 EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 122 EUROPE: BIOMARKERS MARKET, BY PRODUCT, 2019-2026 (USD BILLION)
TABLE 123 EUROPE: BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 124 EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 125 EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
TABLE 126 EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2026 (USD BILLION)
10.3.1 GERMANY
10.3.1.1 Increasing government funding for biomarker research drives the market growth in Germany
TABLE 127 GERMANY: BIOMARKERS MARKET, BY PRODUCT, 2019-2026 (USD BILLION)
TABLE 128 GERMANY: BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 129 GERMANY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 130 GERMANY: BIOMARKERS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
TABLE 131 GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2026 (USD BILLION)
10.3.2 UK
10.3.2.1 Availability of government funding and strategic collaborations with biotech firms have significantly boosted the adoption of biomarkers in the UK
TABLE 132 UK: BIOMARKERS MARKET, BY PRODUCT, 2019-2026 (USD BILLION)
TABLE 133 UK: BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 134 UK: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 135 UK: BIOMARKERS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
TABLE 136 UK: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2026 (USD BILLION)
10.3.3 FRANCE
10.3.3.1 Increasing government investments in genomics & proteomics research to drive the market growth
TABLE 137 FRANCE: BIOMARKERS MARKET, BY PRODUCT, 2019-2026 (USD BILLION)
TABLE 138 FRANCE: BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 139 FRANCE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 140 FRANCE: BIOMARKERS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
TABLE 141 FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2026 (USD BILLION)
10.3.4 REST OF EUROPE (ROE)
TABLE 142 ROE: BIOMARKERS MARKET, BY PRODUCT, 2019-2026 (USD BILLION)
TABLE 143 ROE: BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 144 ROE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 145 ROE: BIOMARKERS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
TABLE 146 ROE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2026 (USD BILLION)
10.4 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: MARKET SNAPSHOT
TABLE 147 ASIA PACFIC: BIOMARKERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 148 ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT, 2019-2026 (USD BILLION)
TABLE 149 ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 150 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 151 ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
TABLE 152 ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2026 (USD BILLION)
10.4.1 CHINA
10.4.1.1 The increasing burden of diseases and growing focus on the development of novel drugs are expected to drive the demand for biomarkers in China
TABLE 153 CHINA: BIOMARKERS MARKET, BY PRODUCT, 2019-2026 (USD BILLION)
TABLE 154 CHINA: BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 155 CHINA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 156 CHINA: BIOMARKERS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
TABLE 157 CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2026 (USD BILLION)
10.4.2 JAPAN
10.4.2.1 Strategic collaborations with leading pharmaceutical companies drive the market growth in Japan
TABLE 158 JAPAN: BIOMARKERS MARKET, BY PRODUCT, 2019-2026 (USD BILLION)
TABLE 159 JAPAN: BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 160 JAPAN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 161 JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
TABLE 162 JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2026 (USD BILLION)
10.4.3 INDIA
10.4.3.1 The growing prevalence of target diseases is expected to support the biomarkers market in India
TABLE 163 INDIA: BIOMARKERS MARKET, BY PRODUCT, 2019-2026 (USD BILLION)
TABLE 164 INDIA: BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 165 INDIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 166 INDIA: BIOMARKERS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
TABLE 167 INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2026 (USD BILLION)
10.4.4 REST OF ASIA PACIFIC (ROAPAC)
TABLE 168 ROAPAC: BIOMARKERS MARKET, BY PRODUCT, 2019-2026 (USD BILLION)
TABLE 169 ROAPAC: BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 170 ROAPAC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 171 ROAPAC: BIOMARKERS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
TABLE 172 ROAPAC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2026 (USD BILLION)
10.5 REST OF THE WORLD (ROW)
TABLE 173 ROW: BIOMARKERS MARKET, BY PRODUCT, 2019-2026 (USD BILLION)
TABLE 174 ROW: BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 175 ROW: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 176 ROW: BIOMARKERS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
TABLE 177 ROW: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2026 (USD BILLION)
10.5.1 LATIN AMERICA (LATAM)
10.5.1.1 Availability of research funding and the rising awareness of advanced sequencing technologies drives the market growth in LATAM
TABLE 178 LATAM: BIOMARKERS MARKET, BY PRODUCT, 2019-2026 (USD BILLION)
TABLE 179 LATAM: BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 180 LATAM: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 181 LATAM: BIOMARKERS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
TABLE 182 LATAM: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2026 (USD BILLION)
10.5.2 MIDDLE EAST AND AFRICA (MEA)
10.5.2.1 Increasing focus on proteomics & genomics research supports market growth in the MEA
TABLE 183 MEA: BIOMARKERS MARKET, BY PRODUCT, 2019-2026 (USD BILLION)
TABLE 184 MEA: BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 185 MEA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 186 MEA: BIOMARKERS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
TABLE 187 MEA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2026 (USD BILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 167)
11.1 KEY PLAYER STRATEGIES
11.1.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY BIOMARKERS PLAYERS
11.2 MARKET SHARE ANALYSIS
FIGURE 27 BIOMARKERS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2020
TABLE 188 BIOMARKERS MARKET: DEGREE OF COMPETITION
11.3 REVENUE ANALYSIS
FIGURE 28 REVENUE ANALYSIS FOR KEY COMPANIES (2017-2020)
11.4 COMPANY EVALUATION QUADRANT
FIGURE 29 BIOMARKERS MARKET (GLOBAL) COMPANY EVALUATION MATRIX, 2020
11.4.1 STAR
11.4.2 PERVASIVE
11.4.3 EMERGING LEADER
11.4.4 PARTICIPANT
11.5 COMPETITIVE LEADERSHIP MAPPING (START-UPS) (2020)
11.5.1 PROGRESSIVE COMPANIES
11.5.2 STARTING BLOCKS
11.5.3 DYNAMIC COMPANIES
11.5.4 RESPONSIVE COMPANIES
FIGURE 30 COMPETITIVE LEADERSHIP MAPPING: BIOMARKERS MARKET
11.5.4.1 COMPETITIVE BENCHMARKING
TABLE 189 COMPANY PRODUCT FOOTPRINT (25 COMPANIES)
TABLE 190 COMPANY APPLICATION FOOTPRINT (25 COMPANIES)
TABLE 191 COMPANY REGION FOOTPRINT (25 COMPANIES)
TABLE 192 COMPANY FOOTPRINT (25 COMPANIES)
11.6 COMPETITIVE SCENARIO
11.6.1 PRODUCT LAUNCHES
TABLE 193 BIOMARKERS MARKET: PRODUCT LAUNCHES, JANUARY 2018-MAY 2021
11.6.2 DEALS
TABLE 194 BIOMARKERS MARKET: DEALS, JANUARY 2018-MAY 2021
11.6.3 OTHERS

12 COMPANY PROFILES (Page No. - 184)
12.1 KEY COMPANIES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 F. HOFFMANN-LA ROCHE LTD
TABLE 195 HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
FIGURE 31 COMPANY SNAPSHOT: HOFFMANN-LA ROCHE LTD (2020)
TABLE 196 HOFFMANN-LA ROCHE LTD: PRODUCT OFFERINGS
TABLE 197 HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS
12.1.2 THERMO FISHER SCIENTIFIC INC.
TABLE 198 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 32 COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC INC (2020)
TABLE 199 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE OFFERINGS
TABLE 200 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 201 THERMO FISHER SCIENTIFIC INC.: DEALS
TABLE 202 THERMO FISHER SCIENTIFIC INC.: OTHERS
12.1.3 ABBOTT LABORATORIES
TABLE 203 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 33 COMPANY SNAPSHOT: ABBOTT LABORATORIES (2020)
TABLE 204 ABBOTT LABORATORIES: PRODUCT OFFERINGS
TABLE 205 ABBOTT LABORATORIES: PRODUCT LAUNCHES
12.1.4 QIAGEN N.V.
TABLE 206 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 34 COMPANY SNAPSHOT: QIAGEN N.V. (2020)
TABLE 207 QIAGEN N.V.: PRODUCT/SERVICE OFFERINGS
TABLE 208 QIAGEN N.V.: PRODUCT LAUNCHES
TABLE 209 QIAGEN N.V.: DEALS
12.1.5 PERKINELMER, INC.
TABLE 210 PERKINELMER, INC.: BUSINESS OVERVIEW
FIGURE 35 COMPANY SNAPSHOT: PERKINELMER, INC. (2020)
TABLE 211 PERKINELMER, INC.: PRODUCT/SERVICE OFFERINGS
TABLE 212 PERKINELMER, INC.: DEALS
12.1.6 MERCK KGAA
TABLE 213 MERCK KGAA.: BUSINESS OVERVIEW
FIGURE 36 COMPANY SNAPSHOT: MERCK KGAA (2020)
TABLE 214 MERCK KGAA: PRODUCT/SERVICE OFFERINGS
TABLE 215 MERK KGAA: DEALS
TABLE 216 MERCK KGAA: OTHERS
12.1.7 BIO-RAD LABORATORIES, INC.
TABLE 217 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 37 COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC. (2020)
TABLE 218 BIO-RAD LABORATORIES, INC.: PRODUCT OFFERINGS
12.1.8 ENZO BIOCHEM, INC.
TABLE 219 ENZO BIOCHEM, INC.: BUSINESS OVERVIEW
FIGURE 38 COMPANY SNAPSHOT: ENZO BIOCHEM, INC. (2020)
TABLE 220 ENZO BIOCHEM, INC.: PRODUCT OFFERINGS
TABLE 221 ENZO BIOCHEM, INC.: OTHERS
12.1.9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
TABLE 222 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
FIGURE 39 COMPANY SNAPSHOT: CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (2020)
TABLE 223 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: SERVICE OFFERINGS
12.1.10 EUROFINS SCIENTIFIC
TABLE 224 EUROFINS SCIENTIFIC.: BUSINESS OVERVIEW
FIGURE 40 COMPANY SNAPSHOT: EUROFINS SCIENTIFIC (2020)
TABLE 225 EUROFINS SCIENTIFIC: SERVICE OFFERINGS
12.1.11 MESO SCALE DIAGNOSTICS, LLC.
TABLE 226 MESO SCALE DIAGNOSTICS, LLC.: BUSINESS OVERVIEW
TABLE 227 MESO SCALE DIAGNOSTICS, LLC: PRODUCT/SERVICE OFFERINGS
12.1.12 STRESSMARQ BIOSCIENCES INC.
TABLE 228 STRESSMARQ BIOSCIENCES INC.: BUSINESS OVERVIEW
TABLE 229 STRESSMARQ BIOSCIENCES INC.: PRODUCT OFFERINGS
12.1.13 DIAMETRA
TABLE 230 DIAMETRA: BUSINESS OVERVIEW
TABLE 231 DIAMETRA: PRODUCT OFFERINGS
12.1.14 SIGNOSIS, INC.
TABLE 232 SIGNOSIS, INC.: BUSINESS OVERVIEW
12.1.15 PRODUCTS OFFERED
TABLE 233 SIGNOSIS, INC.: PRODUCT OFFERINGS
12.2 OTHER COMPANIES
12.2.1 BIOMÉRIEUX SA
TABLE 234 BIOMÉRIEUX SA: COMPANY OVERVIEW
12.2.2 AXON MEDCHEM BV
TABLE 235 AXON MEDCHEM BV: COMPANY OVERVIEW
12.2.3 EKF DIAGNOSTICS HOLDINGS, PLC
TABLE 236 EKF DIAGNOSTICS HOLDINGS, PLC: COMPANY OVERVIEW
12.2.4 MICROCONSTANTS, INC.
TABLE 237 MICROCONSTANTS, INC.: COMPANY OVERVIEW
12.2.5 NORTHEAST BIOANALYTICAL LABORATORIES LLC.
TABLE 238 NORTHEAST BIOANALYTICAL LABORATORIES LLC.: COMPANY OVERVIEW
12.2.6 Q2 SOLUTIONS LLC
TABLE 239 Q2 SOLUTIONS LLC: COMPANY OVERVIEW
12.2.7 JSR LIFE SCIENCES, LLC
TABLE 240 JSR LIFE SCIENCES, LLC: COMPANY OVERVIEW
12.2.8 BIOAGILYTIX LABS
TABLE 241 BIOAGILYTIX LABS.: COMPANY OVERVIEW
12.2.9 CELERION
TABLE 242 CELERION: COMPANY OVERVIEW
12.2.10 ANYGENES
TABLE 243 ANYGENES: COMPANY OVERVIEW
12.2.11 BIOMARKERBAY B. V.
TABLE 244 BIOMARKERBAY: COMPANY OVERVIEW

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 232)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS